CVS健康调整药品目录核心决策 - CVS健康宣布自7月1日起在其最常用的药品目录中优先使用低成本、可互换的生物类似药，以替代强生的银屑病药物Stelara [1] - 此项调整由其药房福利管理部门Caremark执行，将转向使用Stelara的生物类似药版本，例如山德士的Pyzchiva和百康生物的Yesintek [2] - 大多数会员将为其治疗支付0美元的自付费用 [2] 决策背后的商业逻辑与行业影响 - 公司高层表示，扩大采用FDA批准的生物类似药能为客户带来显著节约，同时支持更广泛、更经济地获得成熟疗法 [3] - 生物类似药与普通仿制药不同，后者是简单化学药的精确复制品，而前者源于活细胞，无法被完全精确复制 [3] - Caremark正在扩大特定专科治疗领域的生物类似药覆盖范围，包括多发性硬化症和罕见血液疾病的治疗 [4] - 药品目录是在药房福利管理商支持下管理的、健康计划涵盖的处方药列表，该管理商充当雇主和健康计划的中间人 [4] 其他行业动态摘要 - 意大利Banco BPM银行第一季度净利润超出预期，主要受净手续费收入激增推动，抵消了贷款收入下降的影响 [5] - 据金融时报报道，日产汽车将在全球重组中削减10%的欧洲员工 [5] - 美国及其他国家提议达成电子商务协议，以应对世贸组织谈判的深度僵局 [5] - Fiserv公司因金融解决方案业务表现疲软，季度营收未达预期 [5] - 荷兰量子计算公司QuantWare从英特尔等投资者处筹集了1.78亿美元资金 [5]

Uptake has been very strong with U.S. market share about at 2% and on track for over 3% by the end of the year. Notably, about 80% of CREXONT scripts are coming from IR patients, which is a strong indicator of our successful strategy to pursue the broader Parkinson's market. The patient testimonials have been inspiring, and we have highlighted a few in our earnings presentations. We are highly confident that CREXONT will achieve U.S. peak sales of $300 million to $500 million. Let me now turn to our newest ...

Key Takeaways Amgen beat Q1 estimates with EPS of $5.15 and revenues of $8.62B, both topping consensus.AMGN saw 16 drugs deliver double-digit growth, led by Repatha, Evenity and Uplizna.Amgen raised 2026 guidance as growth in key drugs offset Prolia/Xgeva erosion.Amgen (AMGN) reported first-quarter adjusted earnings of $5.15 per share, which beat the Zacks Consensus Estimate of $4.73 per share. Earnings rose 5% year over year as higher revenues were partially offset by higher operating costs.Total revenues ...

Amneal Pharmaceuticals (NASDAQ:AMRX) Delivers Strong Financial Results and Positive OutlookAmneal Pharmaceuticals reported robust first-quarter financial performance, with earnings per share (EPS) of $0.27 significantly exceeding analyst estimates and revenue reaching $722.52 million.The company raised its adjusted EPS guidance for 2026 to a range of $0.95 to $1.05, reflecting a positive future outlook for the pharmaceutical stock.Strategic initiatives, including the acquisition of Kashiv BioSciences to enh ...